Lanatoside C

Lanatoside C is a cardiac glycoside and can inhibit dengue virus infection with an IC₅₀ value of 0.19µM ^[1]. Lanatoside C can suppress the Na⁺/K⁺-ATPase by decreasing the intracellular K⁺ and increasing the Na⁺ and Ca²⁺, and reduce IL8 production as well as the activities of DNA topoisomerase I and II^[2]. Lanatoside C has been widely used to regulate neuroinflammation and alleviate ulcerative colitis in animal models^[3].

In vitro, Lanatoside C treatment for 24 hours significantly inhibited the proliferation of MKN-45 cells, with an IC₅₀ value of 32.94nM^[4]. Treatment with 1µM Lanatoside C for 24 hours significantly reduced the migration of HeLa cells and induced cell apoptosis, accompanied by a significant upregulation of cleaved caspase-9 and cleaved PARP expression^[5]. 0.6µM of Lanatoside C incubation for 18 hours significantly reduced the mitochondrial membrane potential of Hep3B cells and downregulated the expressions of Bcl-2 family members BID, Bcl-2, and Mcl-1^[6].

In vivo, Lanatoside C treatment via oral administration at a dose of 40mg/kg/day for 42 days significantly inhibited the growth of HuCCT-1 xenograft tumors in mice, without affecting the body weight of the mice^[7]. Oral administration of a 100mg/kg dose of Lanatoside C daily for 10 days significantly alleviated the colitis symptoms in mice induced by dextran sulfate sodium (DSS) and reduced intestinal barrier damage^[8].

References:
[1] Cheung Y Y, Chen K C, Chen H, et al. Antiviral activity of lanatoside C against dengue virus infection[J]. Antiviral research, 2014, 111: 93-99.
[2] Reddy D, Kumavath R, Barh D, et al. Anticancer and antiviral properties of cardiac glycosides: a review to explore the mechanism of actions[J]. Molecules, 2020, 25(16): 3596.
[3] Zhu W, Zhang Z, Wang X. Network pharmacology analysis of Lanatoside C: molecular targets and mechanisms in the treatment of ulcerative colitis[J]. Frontiers in Molecular Biosciences, 2025, 12: 1552360.
[4] Hu Y, Yu K, Wang G, et al. Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/β-catenin/c-Myc signaling pathway in human gastric cancer cell[J]. Biochemical pharmacology, 2018, 150: 280-292.
[5] Duan Y, Chen L, Shao J, et al. Lanatoside C inhibits human cervical cancer cell proliferation and induces cell apoptosis by a reduction of the JAK2/STAT6/SOCS2 signaling pathway[J]. Oncology Letters, 2021, 22(4): 740.
[6] Chao M W, Chen T H, Huang H L, et al. Lanatoside C, a cardiac glycoside, acts through protein kinase Cδ to cause apoptosis of human hepatocellular carcinoma cells[J]. Scientific reports, 2017, 7(1): 46134.
[7] Zhang C, Yang H Y, Gao L, et al. Lanatoside C decelerates proliferation and induces apoptosis through inhibition of STAT3 and ROS-mediated mitochondrial membrane potential transformation in cholangiocarcinoma[J]. Frontiers in Pharmacology, 2023, 14: 1098915.
[8] Yu L, Liu J, Zhao X, et al. Lanatoside C ameliorates DSS-induced colitis with improved intestinal barrier integrity and reduced M1 macrophage polarization[J]. Scientific Reports, 2026.

Lanatoside C是一种强心苷，可抑制登革热病毒感染，IC₅₀值为0.19µM^[1]。Lanatoside C通过降低细胞内K⁺、增加Na⁺和Ca²⁺来抑制Na⁺/K⁺-ATP酶，并减少IL8的产生以及DNA拓扑异构酶I和II的活性^[2]。Lanatoside C已被广泛用于调节动物模型中的神经炎症并减轻溃疡性结肠炎^[3]。

在体外，Lanatoside C处理MKN-45细胞24小时，显著抑制了细胞增殖，IC₅₀值为32.94nM^[4]。1µM的Lanatoside C处理HeLa细胞24小时，显著减少了细胞迁移并诱导了细胞凋亡，同时伴随着cleaved caspase-9和cleaved PARP表达的显著上调^[5]。0.6µM的Lanatoside C孵育Hep3B细胞18小时，显著降低了线粒体膜电位，并下调了Bcl-2家族成员BID、Bcl-2和Mcl-1的表达^[6]。

在体内，每日口服40mg/kg剂量的Lanatoside C，连续42天，显著抑制了小鼠体内HuCCT-1异种移植肿瘤的生长，且未影响小鼠体重^[7]。每日口服100mg/kg剂量的Lanatoside C，连续10天，显著减轻了葡聚糖硫酸钠（DSS）诱导的小鼠结肠炎症状，并减少了肠道屏障损伤^[8]。